

## INOVIQ INVESTOR BRIEFING WEBINAR

**Melbourne, Australia, 4 August 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to invite investors to attend a special online briefing to discuss the Company's recent progress and coming milestones.

The briefing will be presented by CEO, Dr Leearne Hinch; with CFO, Tony Di Pietro and CSO, Dr Greg Rice, attending the Q&A session.

### Session details:

Date: Tuesday, 9 August 2022

Time: 11am Australian Eastern Standard Time (Melbourne time)

Format: Presentation, followed by a Q+A session

Register: Participants can register ahead of time via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_7mw\\_dcYYTsKIBSQ5PdhQvg](https://us02web.zoom.us/webinar/register/WN_7mw_dcYYTsKIBSQ5PdhQvg)

After registering, investors will receive a confirmation email with details on how to join the session.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

### COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

### ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

**FORWARD LOOKING STATEMENTS**

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.